对环氯胍双羟萘酸盐（CI - 501）与4,4'-二乙酰氨基二苯砜（CI - 556）1:1混合物CI - 564抗多重耐药恶性疟原虫的评估。 - Suppr | 超能文献

Evaluation of CI-564, A 1:1 mixture of cycloguanil pamoate (CI-501) and 4,4'-diacetylaminodiphenylsulfone (CI-556), against multiresistant falciparum malarias.

作者信息

Chin W, Contacos P G, Coatney G R, Jeter M H, Alpert E

出版信息

Am J Trop Med Hyg. 1967 Sep;16(5):580-4. doi: 10.4269/ajtmh.1967.16.580.

DOI:10.4269/ajtmh.1967.16.580

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Evaluation of CI-564, A 1:1 mixture of cycloguanil pamoate (CI-501) and 4,4'-diacetylaminodiphenylsulfone (CI-556), against multiresistant falciparum malarias.对环氯胍双羟萘酸盐（CI - 501）与4,4'-二乙酰氨基二苯砜（CI - 556）1:1混合物CI - 564抗多重耐药恶性疟原虫的评估。

Am J Trop Med Hyg. 1967 Sep;16(5):580-4. doi: 10.4269/ajtmh.1967.16.580.

2

The urinary excretion and the antimalarial activity of CI-501 (cycloguanil-pamoate, Camolar) against vivax and falciparum malaria.CI-501（环氯胍扑酸盐，卡莫拉尔）对间日疟和恶性疟的尿排泄及抗疟活性。

Am J Trop Med Hyg. 1966 May;15(3):281-6. doi: 10.4269/ajtmh.1966.15.281.

3

Resistance to cycloguanil pamoate (CI-501) by falciparum malaria in West Pakistan.西巴基斯坦恶性疟原虫对双羟萘酸环氯胍（CI - 501）的耐药性

Am J Trop Med Hyg. 1965 Nov;14(6):925-6. doi: 10.4269/ajtmh.1965.14.925.

4

Susceptibility of Plasmodium falciparum to the drugs used to treat severe malaria (quinine) and to prevent malaria (mefloquine, cycloguanil) in Comoros Union and Madagascar.科摩罗联盟和马达加斯加恶性疟原虫对用于治疗重症疟疾的药物（奎宁）以及预防疟疾的药物（甲氟喹、环氯胍）的敏感性。

S Afr Med J. 2004 Jan;94(1):47-51.

5

DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France.二氢叶酸还原酶（DHFR）基因点突变作为从非洲输入法国的疟疾病例中恶性疟原虫对环氯胍耐药性的预测指标。

Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):460-1. doi: 10.1016/s0035-9203(97)90285-6.

6

A field trial of the effectiveness of cycloguanil pamoate in Rhodesia.帕莫酸环氯胍在罗德西亚有效性的田间试验。

Cent Afr J Med. 1973 Jan;19(1):9-12.

7

Differences in drug response of the sporogonous cycles of three strains of Plasmodium falciparum in Anopheles stephensi.斯蒂芬斯按蚊体内三种恶性疟原虫孢子生殖周期的药物反应差异

Res Commun Chem Pathol Pharmacol. 1970 Jan;1(1):16-24.

8

The repository antimalarial activities of 4,4'-diacetylaminodiphenylsulfone and cycloguanil pamoate (Cl-501) in monkeys relative to local release following parenteral administration.4,4'-二乙酰氨基二苯砜和环氯胍帕莫酸盐（Cl-501）在猴子体内相对于肠胃外给药后局部释放的抗疟药库活性。

J Parasitol. 1965 Jun;51(3):345-9.

9

Malaria. Chemoprophylaxis and chemotherapy.疟疾。化学预防与化疗。

Br Med J. 1971 Apr 10;2(5753):95-8. doi: 10.1136/bmj.2.5753.95.

10

Clinical testing of new antimalarial compounds.新型抗疟化合物的临床试验。

Bull World Health Organ. 1974;50(3-4):203-12.

引用本文的文献

1

Activities of respository preparations of cycloguanil pamoate and 4,4'-diacetyldiaminodiphenylsulfone, alone and in combination, against infections with Plasmodium cynomolgi in rhesus monkeys.双羟萘酸环氯胍和4,4'-二乙酰二氨基二苯砜单独及联合使用时对恒河猴食蟹猴疟原虫感染的抗疟活性。

Antimicrob Agents Chemother. 1984 Nov;26(5):611-42. doi: 10.1128/AAC.26.5.611.

2

Clinical pharmacokinetics of antimalarial drugs.抗疟药物的临床药代动力学。

Clin Pharmacokinet. 1985 May-Jun;10(3):187-215. doi: 10.2165/00003088-198510030-00001.

3

Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection.恶性疟原虫在人体中的最短红细胞外期周期为6.5天的证据，以及用环子孢子蛋白一个区域的合成肽进行免疫可延缓感染的确认。

J Clin Microbiol. 1989 Jul;27(7):1434-7. doi: 10.1128/jcm.27.7.1434-1437.1989.